In Regard to Ciezki et al

To the Editor: We read with interest a recent report from the Cleveland Clinic (1) detailing 5- and 10-year oncologic endpoints for National Comprehensive Cancer Network high-risk prostate cancer (HRCaP) based on a large consecutive cohort treated at that facility. Although the article has much to recommend it, we were disappointed to find a factually incorrect and potentially misleading comment in the Discussion (page 969, paragraph 2); we quote:Comparisons between the ASCENDE-RT trial and this series for bRFS are challenging because only two-thirds of the patients in ASCENDE-RT had HRCaP, whereas the remaining one third had intermediate-risk disease.

http://ift.tt/2vvDWFv